KELLY SUTHERLAND: Open Payments
NPI 1205331600 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$505 in 24 payments from 13 companies in 2025. Trend: 2023 $162 · 2024 $562 · 2025 $505
Food & beverage: $505
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Vanda Pharmaceuticals Inc. | 2 | $64 |
| Axsome Therapeutics, Inc. | 2 | $58 |
| ABBVIE INC. | 3 | $56 |
| Corium, LLC | 2 | $33 |
| Sage Therapeutics, LLC | 2 | $31 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
Products named: CAPLYTA, REXULTI, FANAPT, Auvelity, VRAYLAR, Azstarys, ZURZUVAE, REJOYN.
Industry payments across KY — which companies pay providers there.
